REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Clinical trials for REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with rare cancers: drug blocks tumor growth
Disease control OngoingThis study tests a daily pill called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. The drug works by blocking signals that help tumors grow and form blood vessel…
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
Targeted drug shows promise for kids with rare, Hard-to-Treat cancers
Disease control OngoingThis study tested a drug called larotrectinib in children and young adults (ages 1 to 21) with advanced or returning cancers that have a specific genetic change called an NTRK fusion. The goal was to see if the drug could shrink tumors or stop them from growing. The study include…
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New hope for kids with rare cancers: targeted drug shows promise in early trial
Disease control OngoingThis study tested a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers had come back or were not responding to treatment. The drug targets cancers with specific changes in FGFR genes. The main goal was to see if the drug could shrink tumors. About 2…
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Targeted drug shows promise for kids with Tough-to-Treat cancers
Disease control OngoingThis study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Childhood cancer immunotherapy trial pulled before starting
Disease control TerminatedThis study was designed to test two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with cancers that returned or didn't respond to treatment and have many genetic mutations. The goal was to see if the combination could shrink tumors or help patients l…
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Gene-Guided hope: pediatric MATCH trial aims to outsmart tough childhood cancers
Knowledge-focused OngoingThis study screens children and young adults (ages 1–21) with advanced solid tumors, lymphomas, or related disorders that have come back or not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be tar…
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC